Form 4 for ALKS Alkermes plc.
Accepted 2025-02-14 00:00:00 ET · period of report 2025-02-12 · accession 0001127602-25-004948 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-14 | 2025-02-12+ | ALKS | Hopkinson Craig C. | EVP R, D, Chief Medical Off | M - OptEx | $24.05 | +343.6K | 202.3K | New | +$8.26M |
| DM | 2025-02-14 | 2025-02-12+ | ALKS | Hopkinson Craig C. | EVP R, D, Chief Medical Off | S - Sale+OE | $33.92 | -349.3K | 57.9K | -86% | -$11.85M |
| DM | 2025-02-14 | 2025-02-12+ | ALKS | Hopkinson Craig C. | EVP R, D, Chief Medical Off | M - OptEx | $0.00 | -343.6K | 50.1K | -87% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-02-12 | M | A | 87,566 | $20.03 | 151,166 | D | — | — | |
| 2 | Common | Ordinary Shares | 2025-02-12 | M | A | 111,630 | $19.34 | 262,796 | D | — | — | |
| 3 | Common | Ordinary Shares | 2025-02-12 | S | D | 171,813 | $32.69 | 90,983 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.9998. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| 4 | Common | Ordinary Shares | 2025-02-13 | S | D | 108,833 | $36.02 | 57,875 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.00 to $36.05. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| 5 | Common | Ordinary Shares | 2025-02-13 | M | A | 108,833 | $31.93 | 166,708 | D | — | — | |
| 6 | Common | Ordinary Shares | 2025-02-13 | M | A | 35,586 | $24.59 | 202,294 | D | — | — | |
| 7 | Common | Ordinary Shares | 2025-02-13 | S | D | 35,586 | $34.02 | 166,708 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.07. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| 8 | Common | Ordinary Shares | 2025-02-12 | S | D | 33,108 | $33.27 | 57,875 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.00 to $33.52. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| 9 | Derivative | Employee Stock Option (Right to Buy) | 2025-02-12 | M | D | 87,566 | $0.00 | 0 | D | $20.03 · — to 2030-02-20 | 87,566 Ordinary Shares | (F7) These options are fully vested in accordance with their terms. |
| 10 | Derivative | Employee Stock Option (Right to Buy) | 2025-02-13 | M | D | 35,586 | $0.00 | 71,172 | D | $24.59 · — to 2032-02-18 | 35,586 Ordinary Shares | (F9) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. |
| 11 | Derivative | Employee Stock Option (Right to Buy) | 2025-02-13 | M | D | 108,833 | $0.00 | 0 | D | $31.93 · — to 2029-02-21 | 108,833 Ordinary Shares | (F7) These options are fully vested in accordance with their terms. |
| 12 | Derivative | Employee Stock Option (Right to Buy) | 2025-02-12 | M | D | 111,630 | $0.00 | 50,104 | D | $19.34 · — to 2031-02-22 | 111,630 Ordinary Shares | (F8) Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. |